- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01235975
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years
July 19, 2018 updated by: GlaxoSmithKline
Phase IIIb Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Meningococcal Vaccine [GSK 134612] When Given as One Dose to Healthy Subjects Aged 56 Years or Older
This study evaluates the immunogenicity and safety of the meningococcal conjugate vaccine GSK 134612 given as single dose to healthy adults 56 years or older compared to the meningococcal polysaccharide vaccine MencevaxACWYTM.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
400
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beirut, Lebanon, 1107-2020
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
56 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects who the investigator believes can and will comply with the requirements of the protocol
- A male or female 56 years of age or older at the time of the vaccination.
- Written informed consent obtained from the subject.
- Female subjects of non-childbearing potential may be enrolled in the study.
- Non-child-bearing potential is defined as current tubal ligation, hysterectomy, ovariectomy or post-menopause.
Exclusion Criteria:
- Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- Concurrent participation in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or non-investigational product.
- Extended administration of immunosuppressants or other immune-modifying drugs within six months prior to the vaccination. Inhaled and topical steroids are allowed.
- Any contra-indication to intramuscular and /or subcutaneous injection.
- Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days prior to vaccination and ending 30 days after vaccination. (Vaccination with inactivated influenza vaccines, including H1N1, is allowed at any time during the study as per local recommendations).
- Previous vaccination with meningococcal serogroups A, C, W-135 and Y polysaccharide vaccine within 5 years prior to vaccination.
- Previous vaccination at any time with meningococcal serogroups A, C, W-135 and Y polysaccharide conjugate vaccine.
- Previous vaccination with tetanus toxoid containing vaccine within 5 years prior to vaccination.
- History of meningococcal disease due to serogroups A, C, W-135 or Y.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- Family history of congenital or hereditary immunodeficiency.
- History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
- History of neurological disorders and seizures
- History of Guillain-Barre syndrome.
- Acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or pre-existing laboratory screening tests.
- Acute disease and/or fever at the time of enrolment.
- Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine/product or planned administration during the study period.
- Pregnant or lactating female.
- Current chronic alcohol consumption and/or drug abuse.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A
|
Intramuscular injection
|
Active Comparator: Group B
|
Subcutaneous injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vaccine Response to Meningococcal Antigens (MenA, MenC, MenW-135 and MenY)
Time Frame: One month after vaccination (Month 1)
|
Vaccine response for serum bactericidal assay using rabbit complement (rSBA) antibodies against Neisseria meningitides serogroups A, C , W-135, Y (rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY) was defined as: for initially seronegative subjects [rSBA titer below (<) 1:8], post-vaccination rSBA titer greater than or equal to (≥) 1: 32; for initially seropositive subjects with rSBA titer between 1:8 and 1:128, at least four-fold increase in rSBA titer from pre to post vaccination; and for initially seropositive subjects with rSBA titer ≥1:128, at least two-fold increase in rSBA titer from pre to post vaccination.
|
One month after vaccination (Month 1)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers ≥ the Cut-off Value
Time Frame: At Day 0 and Month 1
|
The cut-off value for the rSBA titers was greater than or equal to (≥) 1:8.
|
At Day 0 and Month 1
|
Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers ≥ the Cut-off Value
Time Frame: At Day 0 and Month 1
|
The cut-off value for the rSBA titers was greater than or equal to (≥) 1:128.
|
At Day 0 and Month 1
|
rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers
Time Frame: At Day 0 and Month 1
|
Antibody titers were presented as geometric mean titers (GMTs).
|
At Day 0 and Month 1
|
Number of Subjects With Anti-polysaccharide Meningococcal Serogroup A (Anti-PSA), Serogroup C (Anti-PSC), Serogroup W-135 (Anti-PSW-135) and Serogroup Y (Anti-PSY) Antibody Concentrations ≥ the Cut-off Value
Time Frame: At Day 0 and Month 1
|
The cut-off value for the anti-polysaccharide concentrations was greater than or equal to (≥) 0.3 micrograms per milliliter (μg/mL).
|
At Day 0 and Month 1
|
Number of Subjects With Anti-PSA, Anti-PSC, Anti-PSW-135 and Anti-PSY Antibody Concentrations ≥ the Cut-off Value
Time Frame: At Day 0 and Month 1
|
The cut-off value for the anti-polysaccharide concentrations was greater than or equal to (≥) 2.0 micrograms per milliliter (μg/mL).
|
At Day 0 and Month 1
|
Anti-PSA, Anti-PSC, Anti-PSW-135 and Anti-PSY Antibody Concentrations
Time Frame: At Day 0 and Month 1
|
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in micrograms per milliliter (μg/mL).
|
At Day 0 and Month 1
|
Number of Subjects With Anti-tetanus Toxoid (Anti-TT) Antibody Concentrations ≥ the Cut-off Value
Time Frame: At Day 0 and Month 1
|
The cut-off value for the anti-TT concentrations was greater than or equal to (≥) 0.1 international units per milliliter (IU/mL).
|
At Day 0 and Month 1
|
Anti-tetanus Toxoid (Anti-TT) Antibody Concentrations
Time Frame: At Day 0 and Month 1
|
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL).
|
At Day 0 and Month 1
|
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Time Frame: Within 4 days (Day 0 to 3) post-vaccination
|
Assessed solicited local symptoms were pain, redness and swelling.
Any = occurrence of the symptom regardless of intensity grade.
Grade 3 pain = significant pain at rest or pain that prevented normal every day activities.
Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site.
|
Within 4 days (Day 0 to 3) post-vaccination
|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Time Frame: Within 4 days (Day 0 to 3) post-vaccination
|
Assessed solicited general symptoms were fatigue,gastrointestinal symptoms, headache and temperature [defined as orally temperature equal to or above (≥) 37.5 degrees Celsius (°C)].
Any = occurrence of any general symptom regardless of intensity grade or relationship to vaccination.
Grade 3 symptom = symptom that prevented normal activity.
Grade 3 temperature = temperature above (>) 39.5 °C.
Related = symptom assessed by the investigator as causally related to the study vaccination.
|
Within 4 days (Day 0 to 3) post-vaccination
|
Number of Subjects With Any Unsolicited Adverse Events (AEs)
Time Frame: Within 31 days (Day 0 to 30) after vaccination
|
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
|
Within 31 days (Day 0 to 30) after vaccination
|
Number of Subjects With Serious Adverse Events (SAEs)
Time Frame: Within 31 days (Day 0 to 30) after vaccination
|
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
|
Within 31 days (Day 0 to 30) after vaccination
|
Number of Subjects With New Onset Chronic Illnesses (NOCI)
Time Frame: Within 31 days (Day 0 to 30) after vaccination
|
NOCIs include autoimmune disorders, asthma, type I diabetes, allergies.
|
Within 31 days (Day 0 to 30) after vaccination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 30, 2010
Primary Completion (Actual)
July 29, 2011
Study Completion (Actual)
August 3, 2011
Study Registration Dates
First Submitted
November 4, 2010
First Submitted That Met QC Criteria
November 4, 2010
First Posted (Estimate)
November 7, 2010
Study Record Updates
Last Update Posted (Actual)
August 20, 2018
Last Update Submitted That Met QC Criteria
July 19, 2018
Last Verified
July 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 113807
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Study Data/Documents
-
Clinical Study Report
Information identifier: 113807Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Dataset Specification
Information identifier: 113807Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: 113807Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Study Protocol
Information identifier: 113807Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: 113807Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: 113807Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infections, Meningococcal
-
Prof. Elizabeth MillerNovartis VaccinesCompletedMeningococcal Meningitis, Serogroup A | Meningococcal Meningitis, Serogroup B | Meningococcal Meningitis, Serogroup C | Meningococcal Meningitis, Serogroup Y | Meningococcal Meningitis, Serogroup WUnited Kingdom
-
EuBiologics Co.,LtdCompletedInfection, MeningococcalKorea, Republic of
-
GlaxoSmithKlineCompletedInfections, Meningococcal | Meningococcal VaccinesIndia, Lebanon, Philippines, Saudi Arabia
-
GlaxoSmithKlineCompletedMeningococcal Disease | Infections, MeningococcalColombia, Panama, Chile
-
GlaxoSmithKlineCompletedMeningococcal Disease | Infections, MeningococcalUnited States
-
Chiron CorporationUnknownMeningococcal Disease; Meningococcal MeningitisUnited Kingdom
-
GlaxoSmithKlineCompletedInfections, Meningococcal | Meningococcal VaccinesGermany, France
-
GlaxoSmithKlineCompletedMeningococcal Disease | Infections, MeningococcalUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompletedMeningitis | Meningococcal Infections | Meningococcal Meningitis | Invasive Meningococcal DiseaseUnited States
-
GlaxoSmithKlineCompletedPregnancy | Meningococcal Disease | Infections, MeningococcalUnited States
Clinical Trials on Meningococcal vaccine GSK 134612
-
GlaxoSmithKlineCompletedInfections, MeningococcalUnited States, Canada
-
GlaxoSmithKlineCompletedMeningococcal InfectionMexico, Lebanon
-
GlaxoSmithKlineCompletedInfections, MeningococcalFinland
-
GlaxoSmithKlineCompletedInfections, MeningococcalThailand, Panama, Philippines
-
GlaxoSmithKlineCompletedInfections, MeningococcalSweden, Denmark
-
GlaxoSmithKlineCompletedInfections, MeningococcalUnited States
-
GlaxoSmithKlineCompletedInfections, MeningococcalDenmark
-
GlaxoSmithKlineCompletedInfections, MeningococcalUnited States
-
GlaxoSmithKlineCompletedHepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Streptococcus Pneumoniae VaccinesSpain, Germany, Poland
-
GlaxoSmithKlineCompletedInfections, MeningococcalGermany, France